Summary A type I interferon resistant variant (P-MIP101) of the poorly differentiated human colon cancer cell MIPIOI has a more aggressive phenotype in vhvo in the nude mouse. Subcutaneous tumours grew at twice the rate of MIPIOI. but with similar morphology. P-MIP101 also produced liver metastases at a higher frequency. P-MIP101 tumours were al., 1988). Six xenografts each of the resistant and sensitive cell lines were excised, snap frozen and mechanically disassociated. Subcellular debris were removed by centrifugation on a sucrose gradient. The cells were stained in a hypotonic propidium iodide buffer and the stained nuclei were analysed on an EPIV V flow cytometer (Coulter Electronics. Hialeah. FL).
. Interferons have cvtostatic effects on colorectal cancer cells both in vivo and in vitro and can increase the expression of tumour markers such as carcinoembrovonic antigen (CEA) (Toth & Thomas, 1990 and Kondo et al.. 1987) . The mechanism of growth inhibition of transformed cells by interferons is unknown.
Colorectal cancers are amongst the most difficult tumours to treat once metastatic spread has occurred and are refractive to both chemotherapy and radiation therapy (Moertel. 1988; Steel & Thomas. 1988) . The antiproliferative effects of interferons make them potential antineoplastic agents. Clinical trials of a and y interferon in combination with 5-fluorouracil (5FUra) and tumour necrosis factor (TNF) in metastatic colorectal cancer are currently underway (Wadler et al.. 1990a; Abbruzzese et al., 1989 : Ajani et al.. 1989 .
As part of a study of the mechanisms of interferon action on colorectal cancer cells, we have produced a clone of the poorly differentiated colorectal carcinoma cell MIPlOI (Niles et al.. 1987) (Wagner et al.. 1990) . Briefly. the spleen was exposed through a short incision and 2 x 106 cells in 100 t of PBS were slowly injected into its lower pole. The spleen was replaced in the abdomen and the abdominal wall and skin closed by clips.
Flow cvtometrv
Flow cy-tometric DNA quantitative analysis was performed by the Nichols Institute (San Juan Capistrano. CA) using a modification of the Krishan method (Dressler et al., 1988) . Six xenografts each of the resistant and sensitive cell lines were excised, snap frozen and mechanically disassociated. Subcellular debris were removed by centrifugation on a sucrose gradient. The cells were stained in a hypotonic propidium iodide buffer and the stained nuclei were analysed on an EPIV V flow cytometer (Coulter Electronics. Hialeah. FL).
Interferon uptake assays P interferon (100 fig) was labeled with 1 mCi of Na'25I to a specific activity, of approximately 5 plCi Lg-' using the chlorBr. J. Cancer (1992) . 65, [365] [366] [367] [368] (D MacTnillan Press Ltd.. 1992 amine T procedure (Greenwood et al.. 1963) . and ran as a single band on 10% SDS-PAGE. Confluent monolayers of MIPIOI and frMIP101 (1 x 106 cells) were incubated at 37°C for 90 min with vanrous concentrations of '5I-P interferon in PBS containing BSA (1 mg ml-'). The cells were washed three times and solubilised in 1 M NaOH. The uptake of frINF was determined by measuring the level of cell associated '25I-P interferon. Nonspecific uptake was determined bv measunrng '1I-P interferon uptake in the presence of a 250-fold excess of unlabelled P interferon.
Results
We selected for a i interferon resistant variant of the poorlv differentiated human colon carcinoma cell line MIPIOI. b; culturing cells in the presence of 25.000 units ml-1 of recombinant human P interferon for 3 months. The 0 interferon in the media was replenished every 7 days. The resulting cell line frMIPIOI. was resistant to growth inhibition by P interferon. Figure 1 shows 2,500 5,000 16,750 24,500 50,000
Beta interferon U ml-' Morikawa et al. (1990) also isolated interferon resistant clones from an interferon sensitive human colorectal cancer cell line KM12C. They reported that cells made resistant to a interferon became resistant to both type I and type II interferons. However, cells made resistant to type II interferons still showed sensitivity to type I interferon.
In this study. the parent line MIPIOI shows some natural resistance to the antiproliferative effects of P interferon (onlv 40% growth inhibition at 2.500 U ml-'. Figure 1 ). However.
this is not uncommon in colorectal cancer cell lines (Toth & Thomas, 1990 (Schiller et al.. 1990; Wadler et al.. 1990b) . Clinical trials using alpha and gamma interferon in combination with 5FUra are underway as are studies with TNF (Wadler et al.. 1990c; Abbruzzese et al.. 1989) . Treatment of colorectal cancer patients with alpha interferon and 5FUra has shown promising results (Wadler et al.. 1990a) . In vitro, the Type I interferons appear to be more potent modulators of 5FUra cytotoxicity when compared to Type II (Wadler et al.. 1990b 
